EMEA-002578-PIP01-19
Key facts
| Active substance |
Autologous CD34+enriched cells from patients with Fanconi anaemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene (PGK-FANCA-WPRE)
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0114/2020
|
| PIP number |
EMEA-002578-PIP01-19
|
| Pharmaceutical form(s) |
Dispersion for infusion
|
| Condition(s) / indication(s) |
Treatment of Fanconi anaemia subtype A
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Rocket Pharmaceuticals, Inc.
E-mail: mz@rocketpharma.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|